Belimumab (BENLYSTA®) Pregnancy Registry
WEUKBRE6076: Belimumab (BENLYSTA) Pregnancy Registry Protocol
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Innsbruck, Austria, 6020
- GSK Investigational Site
-
-
-
-
-
LiEge, Belgium, 4000
- GSK Investigational Site
-
-
-
-
-
Quebec, Canada, H4T 1V6
- GSK Investigational Site
-
-
-
-
-
Paris, France, 75651
- GSK Investigational Site
-
-
-
-
-
Duesseldorf, Germany, 40225
- GSK Investigational Site
-
-
-
-
-
Tel Hashomer, Israel, 52621
- GSK Investigational Site
-
-
-
-
-
Pisa, Italy, 56126
- GSK Investigational Site
-
-
-
-
-
Almada, Portugal, 2805-267
- GSK Investigational Site
-
-
-
-
-
Bilbao, Spain, 48013
- GSK Investigational Site
-
-
-
-
-
Stockholm, Sweden, SE-17176
- GSK Investigational Site
-
-
-
-
-
Bern, Switzerland, 3010
- GSK Investigational Site
-
St Gallen, Switzerland, 9007
- GSK Investigational Site
-
Zuerich, Switzerland, 8006
- GSK Investigational Site
-
-
-
-
North Carolina
-
Wilmington, North Carolina, United States, 28401
- GSK Investigational Site
-
Wilmington, North Carolina, United States, 28401-3331
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pregnant women containing sufficient evidence to confirm that exposure to commercially supplied belimumab occurred within the 4 months prior to and/or during pregnancy
- Pregnant women with sufficient information to classify the pregnancy as prospective or retrospective (ie,whether the outcome of pregnancy was known at the time of first contact with the registry)
- Pregnant women with full contact information to allow for follow-up (name, address, telephone number/email address) and contact information for applicable HCPs if initial reporter is the pregnant woman
- Consent provided by the pregnant woman for her participation and assent for participation of her infant.
Exclusion Criteria:
- Reported cases that do not meet the minimum inclusion criteria for registry enrollment will be ineligible for inclusion in the registry
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Pregnant women taking belimumab
Any women with belimumab exposure within the 4 months prior to and/or during pregnancy
|
Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
|
|
Infants
Infants through the first year of life whose mothers were exposed to belimumab during pregnancy
|
Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Birth defects
Time Frame: Up to one year after birth
|
The registry will define and code birth defects with criteria specified by Centers for Disease Control and Prevention (CDC)'s Metropolitan Atlanta Congenital Defects Program (MACDP)
|
Up to one year after birth
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Other pregnancy outcomes
Time Frame: At birth
|
Other pregnancy outcomes including spontaneous miscarriage, live birth (including pre-term birth and small for gestational age), stillbirth, and elective termination
|
At birth
|
|
Infant outcomes
Time Frame: Up to 1 year after birth
|
Serious and/or clinically significant infections
|
Up to 1 year after birth
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 114256
- WEUKBRE6076 (Other Identifier: GSK)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.